Reynolds MR, Gong T, Li S, et al. - Researchers herein constructed a Markov cohort simulation model to ascertain the cost‐effectiveness of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in patients with chronic kidney disease who were hospitalized with acute myocardial infarction or unstable angina. A sample of 14,300 patients identified using the Medicare 20% sample was mainly used to retrieve model inputs. They projected the outcomes with respect to survival, quality‐adjusted life‐years, costs, and cost‐effectiveness over a 20‐year time horizon. Per outcomes, PCI and CABG were both linked with markedly raised costs as well as gains in quality‐adjusted life expectancy among patients with chronic kidney disease and high‐risk coronary artery disease presentations. Incorporation of long‐term costs led to incremental cost‐effectiveness ratios of $65,326 per quality‐adjusted life‐year gained for PCI vs medical therapy, and $101,565 for CABG vs PCI. These incremental cost‐effectiveness ratios suggest intermediate value in health economic terms.